elacytarabine
Small moleculeexperimental
Clinical trial activity
9 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00232726)
Timeline
Indications
Mechanism of action
- RNAINHIBITOR
RNA inhibitor
Enters cells by a nucleoside transporter-independent mechanism and exhibits longer intracellular retention with accompanying longer inhibition of DNA synthesis. It also causes transient inhibition of RNA synthesis
- DNAINHIBITOR
DNA inhibitor
Enters cells by a nucleoside transporter-independent mechanism and exhibits longer intracellular retention with accompanying longer inhibition of DNA synthesis. It also causes transient inhibition of RNA synthesis
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O- Mol. weight
- 507.67 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105665 ↗
Also known as
- 5'-oleoyl cytarabine
- 5'-oleoyl cytosine arabinoside
- 5'-oleyl-ara-c
- cp4055
- cp 4055
- cp-4055
- cp-4055
- cp-4055
- cp-4055
- elacyt
- elacytarabine
- elacytarabine
- elacytarabine
- elacytarabine
- elacytarabine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01783964 | Phase 1 | Feb 1, 2013 | Aqualis |
| NCT01258816 | Phase 1 | Oct 1, 2010 | Aqualis, Banook Group, Cardiff University, INC Research, Learn & Confirm, Theradex |
| NCT01147939 | Phase 3 | Jun 1, 2010 | Aqualis, Duke University, University of Texas, San Antonio |
| NCT01035502 | Phase 2 | Dec 1, 2009 | Aqualis, Duke University, INC Research, Theradex |
| NCT00831636 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2008 | Aqualis, University of Milan |
| NCT00498407 | Phase 2 | May 1, 2007 | Aqualis, The Beatson West of Scotland Cancer Centre |
| NCT00498836 | Phase 2 | Mar 1, 2007 | Aqualis, University of Oslo |
| NCT00405743 | Phase 1/Phase 2 (Phase 2) | May 1, 2006 | Aqualis, University of Texas at Houston |
| NCT00232726 | Phase 2 | Sep 1, 2005 | Aqualis, University of Oslo |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aqualis | For profit | 9 | 9 | 3 | 2005 |
| Duke University | Academic/Hospital | 2 | 0 | 2 | 2009 |
| INC Research | For profit | 2 | 0 | 2 | 2009 |
| Theradex | For profit | 2 | 0 | 2 | 2009 |
| University of Oslo | Academic/Hospital | 2 | 0 | 1 | 2005 |
| Banook Group | For profit | 1 | 0 | 1 | 2010 |
| Cardiff University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Learn & Confirm | For profit | 1 | 0 | 1 | 2010 |
| The Beatson West of Scotland Cancer Centre | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2010 |
12 organizations
Page 1 / 1